Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 260

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 260
---
 landlord with a bank guarantee of approximately of $7 (NIS 27 thousand) which is valid until February 2025.

<div align='center'>F-13</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

Future minimum lease payments under non-cancelable
operating leases as of June 30, 2024 are as follows:

| 2024 |     | USD | 33 |
|:-----|:----|:----|---:|
|      |     | $   | 33 |

The Company elected to apply the practical
expedients permitted under the transition guidance in ASU 2016-02, and the Company also elected not to apply the recognition requirements
in ASU 2016-02 to short-term leases (less than 12 months) as of the adoption date. As such, there was no impact on the Company’s
financial statements as a result of adopting ASU 2016-02.

| 6. | In 2019, a controversy has                                                                                                              
 arisen between the Company and CSL Behring GmbH, or CSL, whether certain unshipped minimum purchase commitments for fibrinogen from     
 2018 to 2020 are to be paid by the Company pursuant to a Framework Supply Agreement dated March 8, 2016, or Framework Supply Agreement, 
 by and between the Company and CSL, whereby CSL agreed to supply the Company with fibrinogen. On January 14, 2020, the Company received 
 a termination letter, or CSL Termination Letter. In the CSL Termination Letter, CSL demanded a total amount of $820, claiming it        
 was owed the minimum purchase commitment amounts under the Framework Supply Agreement not paid by the Company in 2018 and 2019. In      
 a subsequent correspondence, CSL additionally demanded interest and damages for lost profit, with an aggregate demand amount of $1,476. 
 The Company has disputed CSL’s payment demand and contends that CSL’s demands are baseless under the Framework Supply                   
 Agreement, as the minimum purchase commitment under the Framework Supply Agreement is conditional upon first obtaining approval of      
 the FDA and the European Medicines Evaluation Agency, or EMEA, and other quality and clinical milestones, none of which has occurred.   
 Notwithstanding,